Department Pediatric Oncology, Emma Children's Hospital, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
Cancer. 2024 Apr 15;130(8):1349-1358. doi: 10.1002/cncr.35148. Epub 2023 Dec 15.
The aim of this study is to evaluate how cumulative burden of clinically relevant, self-reported outcomes in childhood cancer survivors (CCSs) compares to a sibling control group and to explore how the burden corresponds to levels of care proposed by existing risk stratifications.
The authors invited 5925 5-year survivors from the Dutch Childhood Cancer Survivor Study (DCCSS LATER) cohort and their 1066 siblings to complete a questionnaire on health outcomes. Health outcomes were validated by self-reported medication use or medical record review. Missing data on clinically relevant outcomes in CCSs for whom no questionnaire data were available were imputed with predictive mean matching. We calculated the mean cumulative count (MCC) for clinically relevant outcomes. Furthermore, we calculated 30-year MCC for groups of CCSs based on primary cancer diagnosis and treatment, ranked 30-year MCC, and compared the ranking to levels of care according to existing risk stratifications.
At median 18.5 years after 5-year survival, 46% of CCSs had at least one clinically relevant outcome. CCSs experienced 2.8 times more health conditions than siblings (30-year MCC = 0.79; 95% confidence interval [CI], 0.74-0.85 vs. 30-year MCC = 0.29; 95% CI, 0.25-0.34). CCSs' burden of clinically relevant outcomes consisted mainly of endocrine and vascular conditions and varied by primary cancer type. The ranking of the 30-year MCC often did not correspond with levels of care in existing risk stratifications.
CCSs experience a high cumulative burden of clinically relevant outcomes that was not completely reflected by current risk stratifications. Choices for survivorship care should extend beyond primary tumor and treatment parameters, and should consider also including CCSs' current morbidity.
本研究旨在评估儿童癌症幸存者(CCS)在临床上相关的、自我报告的结局方面的累积负担与同胞对照组相比如何,并探讨这种负担与现有风险分层所提出的护理水平的对应关系。
作者邀请了来自荷兰儿童癌症幸存者研究(DCCSS LATER)队列的 5925 名 5 年幸存者及其 1066 名兄弟姐妹完成了一份关于健康结局的问卷。健康结局通过自我报告的药物使用或医疗记录审查进行验证。对于没有问卷数据的 CCS 中临床上相关结局的缺失数据,使用预测均值匹配进行了估算。我们计算了临床上相关结局的平均累积计数(MCC)。此外,我们根据主要癌症诊断和治疗对 CCS 组进行了 30 年 MCC 排名,并将排名与现有风险分层的护理水平进行了比较。
在 5 年生存后的中位 18.5 年,46%的 CCS 至少有一种临床上相关的结局。CCS 经历的健康状况是兄弟姐妹的 2.8 倍(30 年 MCC=0.79;95%置信区间[CI],0.74-0.85 与 30 年 MCC=0.29;95% CI,0.25-0.34)。CCS 临床上相关结局的负担主要由内分泌和血管疾病组成,且因主要癌症类型而异。30 年 MCC 的排名通常与现有风险分层中的护理水平不一致。
CCS 经历了临床上相关结局的高累积负担,这在现有风险分层中并未得到完全反映。生存护理的选择不应仅限于原发性肿瘤和治疗参数,还应考虑包括 CCS 当前的发病率。